The MS-STAT2 trial of a high-dose simvastatin has failed to slow progression of disability in patients with secondary ...

The following is a summary of “Untackling the economics of Multiple Sclerosis: a systematic review of economic evaluations of disease-modifying therapies indicated for Multiple Sclerosis,” published ...

People with multiple sclerosis (MS) often stop taking disease-modifying therapy ... patients individually when considering DMT discontinuation and advocate for future research to determine whether ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently compiled a list of the 11 Trending AI Stocks on Latest News and Ratings. In this article, we are going to take a ...

Mapping cell types in MS lesions reveals unique tissue niches and interactions, offering insights into the molecular drivers of multiple sclerosis progression.

In recent months, artificial intelligence (AI) stocks have been a focus of stock-split stocks. This began last year, as Amazon and Alphabet initiated splits when pre-split stock prices exceeded $2,000 ...

BlackDoctor.org spoke with neurologist and MS specialist Dr. Mitzi Williams to discuss why MS gets overlooked in the Black ...

Research Letter: Accumulation of Epstein-Barr virus–induced cross-reactive immune responses is associated with multiple ...

Financial earnings results and cloud market share for third- quarter 2024 include AWS, Microsoft and Google Cloud via GCP, Azure and AWS cloud.

Recent research has shown that, in MS—especially in the progressive stages—cells in the brain that normally support nerve ...

The prevalence of MS in Australia has been increasing at an accelerating rate in recent years, according to a report from MS Australia.